ReiThera News and Resources

ReiThera has entered into a Master Service Agreement (MSA) with SillaJen to support the manufacturing of the SJ-600 series, an innovative anticancer virus platform. The agreement appoints ReiThera as the Contract Development and Manufacturing Organization (CDMO) for the platform, enabling

ReiThera, in collaboration with the Sabin Vaccine Institute, has commenced a pivotal role in addressing the Marburg virus outbreak by manufacturing and shipping around 700 investigational vaccine doses to Rwanda. This shipment supports a Phase 2 rapid response clinical trial

ReiThera, a CDMO company dedicated to technology and process development and GMP manufacturing has initiated a Phase 2 clinical trial in Uganda for a vaccine targeting the Sudan ebolavirus, marking a significant step in addressing life-threatening infectious diseases. The trial

ReiThera, a contract manufacturing organisation (CDMO), has announced the appointment of Stefano Colloca as its new Chief Executive Officer. The announcement was made on 6th July 2024. Stefano Colloca, a seasoned leader in viral vector technologies, co-founded and directed numerous